The Future Of Gene Patch Technology

Presenter: Neal Howard
Guest: Dr. Stephen Shrewsbury
Guest Bio: Dr. Shrewsbury was most recently Senior Vice President, Preclinical & Clinical Development and Chief Medical Officer of AVI BioPharma (now Sarepta Therapeutics). From 2005 until 2009, he held similar roles at Adamas Pharmaceuticals and MAP Pharmaceuticals. While at MAP, Dr. Shrewsbury lead four inhaled drug programs and took two lead candidates (in asthma and migraine) from preclinical stage to Phase III in 18 months. Prior to his experience in biotechnology, Dr. Shrewsbury spent 10 years with Glaxo and Chiron launching notable respiratory programs such as Seretide in Europe and Flovent and Advair in the US. Dr. Shrewsbury received his medical degree from the University of Liverpool, UK and spent 13 years working in the UK National Health Service before entering the pharmaceutical industry.

Segment Overview
Dr. Stephen Shrewsbury tells his story. The future of gene patch technology is also touched upon.

Transcription

Health Professional Radio

Neal Howard: Hello. You’re listening to Health Professional Radio. I’m your host Neal Howard, glad that you’re with us today. Our guest in studio today is Dr. Stephen Shrewsbury. He’s been in practice for quite some time now. His 30-years career has taken him from the intimate setting of an English family practice to actually developing drugs and creating and researching in gene patch technology.

Gene patch technology has the potential of protecting us from all sorts of ailments, some of which are kept in labs to keep us safe, other might be used for maybe chemical or biological attack. And we can change our DNA and change the way that our bodies react to a lot of the ailments that are out there.

How do you doing today, Steve?

Want to continue reading? Please log-in or register to see the Full Transcript.